Other Routine +

Pharmadrug, Pharmather to explore PD-001 for hantavirus

PharmaTher Advances Antiviral Pipeline with Hantavirus Candidate Amidst Ketamine Monetization

By The Northwire Desk — AI Analysis May 13, 2026 · 10:08 PHRM · 0.085 Pharmather Holdings Ltd

Executive Summary

Headline: PharmaTher's Sairiyo Therapeutics to Explore PD-001, Its Patented Reformulated Cepharanthine, for Hantavirus.
Date: 2026-05-13.
Core Development: Independent research demonstrates cepharanthine inhibits Hantavirus pseudovirus (HTNVpv) in mouse models with high efficacy (~94% inhibition at 180 mg/kg/day).
Regulatory Status: Sairiyo Therapeutics received approval from an Australian Human Research Ethics Committee to initiate a first-in-human Phase 1 clinical study of PD-001 in healthy volunteers.
Objective: Evaluate safety, tolerability, pharmacokinetics, and bioavailability of the enteric-coated oral formulation (PD-001).
Ownership Structure: Sairiyo Therapeutics is 49% owned by PharmaTher Holdings Ltd. and 51% owned by Pharmadrug Inc.
Intellectual Property: PD-001 protected by US Patent US10576077 (expires March 23, 2036).
Historical Context: PD-001 was previously the subject of a $3.4 million contract from the Defense Threat Reduction Agency (DTRA) for Ebola virus-related research.

Material Impact

Pipeline Progression: The news confirms progression from preclinical mouse data to regulatory approval for Phase 1 human trials in healthy volunteers. This is a standard but necessary step for clinical validation.
Financial Impact: No immediate revenue generation or capital raise announced. The potential financial upside remains speculative and distant, contingent on successful Phase 1/2 results and eventual commercialization.
Market Expectations: Given the company's history of selling its primary cash-generating asset (Ketamine ANDA) in late 2025 for milestone payments, the market has already priced in a transition to pipeline monetization. This news is incremental rather than transformative.
Stock Price Reaction Context: The stock price has declined significantly from $0.54 (July 2025) to $0.09 (May 2026), despite the earlier announcement of the Ketamine ANDA sale ($25M+ potential). This suggests investor skepticism regarding the timing and certainty of future cash flows from pipeline assets.
Subsidiary Ownership: PharmaTher only owns 49% of Sairiyo, meaning the full financial benefit of any success is shared with Pharmadrug Inc., diluting the direct impact on PharmaTher's bottom line compared to a wholly-owned asset.
Risk Profile: Phase 1 healthy volunteer studies assess safety and bioavailability, not therapeutic efficacy in patients. Failure at this stage or subsequent stages would negate the value of the patent and research investment.

PHRM · Price

Company Overview

Company: PharmaTher Holdings Ltd. (PHRM).
Flagship Project: Ketamine-based therapies and delivery platforms.
- Ketamine ANDA: Sold in late 2025 for potential >$25M consideration; retains profit-sharing rights.
- Long-Acting Injectables (LAI): Partnership with Oakwood Laboratories for neuropsychiatric indications (Parkinson's, TRD).
- Microneedle Patches: PharmaPatch™ platform targeting peptides, GLP-1s, and psychedelics.
Subsidiary Focus: Sairiyo Therapeutics (49% owned) focuses on Cepharanthine reformulations for viral infections (Hantavirus, previously Ebola).
Strategic Shift: Moving from generic asset monetization to proprietary platform development (AI discovery, patches, peptides).

More from Pharmather Holdings Ltd